You are now leaving XTANDI.com
The website you are about to visit is not owned or controlled by Astellas. Astellas are not responsible for the information or services on this site.
NORTHBROOK, Ill., Oct. 24, 2017 /PRNewswire/ -- Astellas today announced the five C3 Prize finalists chosen from more than 160 entries to present their ideas to change cancer care in a live forum at the Union for International Cancer Control (UICC) World Cancer Leaders' Summit (WCLS) on November 13th in Mexico City. The Astellas Oncology C3 Prize is a global challenge designed to acknowledge and support non-medicine innovations to improve the cancer care experience for patients, caregivers and their loved ones. Following the live pitches, Astellas will award one Grand Prize Winner a $50,000 grant and a personal business consultation with Robert Herjavec, technology entrepreneur, star of ABC's Emmy Award-winning hit television show Shark Tank and former cancer caregiver.
"The quality of the Astellas Oncology C3 Prize submissions is a testament to Astellas' philosophy of tapping into the collective genius of people around the world to generate innovation," said Herjavec. "Each of the finalist ideas has the potential to bring non-treatment based innovation in cancer care to reality, and I'm looking forward to meeting with this year's Grand Prize Winner."
Applicants to this year's challenge included patients, caregivers, healthcare providers and technology entrepreneurs from more than 20 countries who submitted ideas in four areas where patients living with cancer and the overall cancer community face some of the toughest obstacles: navigating the health care system, adhering to complex medical care requirements, coordinating care and surviving life post-treatment. The five finalists are:
The finalists will present their ideas at the WCLS to a panel of judges including Ambassador Sally Cowal, senior vice president, Global Cancer Control at the American Cancer Society, Nick Grant, executive director, International Partnerships at Cancer Research UK, Chihiro Hosoya, senior manager, New Business Incubator at Astellas, and Mark Reisenauer, senior vice president, Oncology Business Unit at Astellas.
"We are again thrilled with the number and quality of submissions received for this year's C3 Prize," said Reisenauer, whose own personal experience caring for his late father influenced the development and launch of the C3 Prize.
In addition to the Grand Prize Winner, the other four finalists will each receive $12,500 from Astellas and all five finalists will receive a one-year nights and weekends' membership to MATTER, a healthcare innovation community, to help bring their ideas to life.
For more information, visit www.C3Prize.com.
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at www.astellas.us. You can also follow us on Twitter at @AstellasUS, Facebook at www.facebook.com/AstellasUS or LinkedIn at www.linkedin.com/company/astellas-pharma.
The Union for International Cancer Control (UICC) is dedicated to taking the lead in convening, capacity building and advocacy initiatives that unite the cancer community to reduce the global cancer burden, promote greater equity, and integrate cancer control into the world health and development agenda.
Founded in 1933 and based in Geneva, Switzerland, UICC is the largest and oldest international cancer organisation. With over 1,000 members and 56 partners across 162 countries, UICC features the world's major cancer societies, ministries of health, research institutes, patient groups, and industry leaders.
For more information, visit www.uicc.org.
MATTER is a community of entrepreneurs, innovators and industry leaders working together to harness technology to improve health and healthcare. MATTER connects and promotes collaboration between entrepreneurs, scientists, physicians, investors and industry leaders in order to bring next-generation products and services to market that improve quality of care and save lives. For more information, visit www.matterchicago.com.
SOURCE Astellas Pharma Inc.
This website is intended for U.S. residents only. This website contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, or in different dosages. Nothing contained herein should be considered a solicitation, promotion or advertisement for any drug including those under development. Any information on the products contained herein is not intended to provide medical advice nor should be used as a substitute for the advice provided by your physician or other healthcare provider.